Subject:Announcement of the approval of the Company's quadrivalent influenza vaccine from China's National Medical Products Administration

Close

Today's Information

Provided by: ADIMMUNE CORPORATION
SEQ_NO	1	Date of announcement	2022/02/11	Time of announcement	13:52:21
Subject	Subject:Announcement of the approval of the Company's quadrivalent influenza vaccine from China's National Medical Products Administration
Date of events	2022/02/11	To which item it meets	paragraph 51
Statement	1.Date of occurrence of the event:2022/02/11 2.Company name:Adimmune Corporation 3.Relationship to the Company (please enter "head office" or "subsidiaries"):head office 4.Reciprocal shareholding ratios:NA 5.Cause of occurrence:The marketing authorization of the Company's quadrivalent influenza vaccine is granted by China's National Medical Products Administration 6.Countermeasures:To release this material information 7.Any other matters that need to be specified:Upon receiving the marketing authorization from China's National Medical Products Administration, the Company will initiate the marketing of quadrivalent influenza vaccine for adults. It will have positive impacts on the Company's sales and finances.